We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.44%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$256M
AUM Growth
-$27.3M
Cap. Flow
-$13M
Cap. Flow %
-5.06%
Top 10 Hldgs %
49.1%
Holding
75
New
10
Increased
14
Reduced
12
Closed
12
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.88M
2
SHPG
Shire pic
SHPG
+$9.33M
3
ARRY icon
Array Biopharma Inc
ARRY
+$5.99M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$3.81M
5
SAGE icon
Sage Therapeutics
SAGE
+$3.23M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$12.6M
2
ENTL icon
Entellus Medical, Inc. Common Stock
ENTL
+$8.32M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.06M
4
AMGN icon
Amgen
AMGN
+$6.28M
5
BIIB icon
Biogen
BIIB
+$6.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$18.3M 7.15%
205,522
+15,500
+8% +$1.49M
2016 Q4
5 quarters
SHPG
2
DELISTED
Shire pic
SHPG
$14.8M 5.77%
99,000
+67,800
+217% +$9.33M
2017 Q4
1 quarter
ARRY icon
3
DELISTED
Array Biopharma Inc
ARRY
$13.9M 5.42%
851,500
+374,000
+78% +$5.99M
2016 Q4
5 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$13.9B
$12.8M 4.98%
154,000
+117,000
+316% +$9.88M
2017 Q3
2 quarters
BIIB icon
5
Biogen
BIIB
$34.8B
$12.5M 4.87%
45,608
-19,400
-30% -$6.02M
2016 Q4
5 quarters
REGN icon
6
Regeneron Pharmaceuticals
REGN
$82B
$12.4M 4.84%
36,030
-4,800
-12% -$1.67M
2016 Q4
5 quarters
SAGE icon
7
DELISTED
Sage Therapeutics
SAGE
$11.3M 4.43%
70,496
+19,000
+37% +$3.23M
2016 Q4
5 quarters
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$129B
$11.1M 4.34%
68,222
-7,200
-10% -$1.18M
2016 Q4
5 quarters
GILD icon
9
Gilead Sciences
GILD
$195B
$9.9M 3.86%
131,284
+8,500
+7% +$676K
2016 Q4
5 quarters
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$8.83M 3.45%
370,000
+55,000
+17% +$1.73M
2016 Q4
5 quarters
EXEL icon
11
Exelixis
EXEL
$15.6B
$8.6M 3.35%
388,334
-22,000
-5% -$608K
2016 Q4
5 quarters
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$8.07M 3.15%
72,441
– –
2016 Q4
5 quarters
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$7.52M 2.93%
492,930
– –
2017 Q1
4 quarters
HALO icon
14
Halozyme
HALO
$13.8B
$7.03M 2.74%
358,633
+76,000
+27% +$1.47M
2016 Q4
5 quarters
LGND icon
15
Ligand Pharmaceuticals
LGND
$5.95B
$6.94M 2.71%
67,326
+20,839
+45% +$2.06M
2016 Q4
5 quarters
INCY icon
16
Incyte
INCY
$23B
$6.08M 2.37%
72,975
– –
2016 Q4
5 quarters
IONS icon
17
Ionis Pharmaceuticals
IONS
$7.33B
$5.58M 2.18%
126,500
+75,000
+146% +$3.81M
2017 Q1
4 quarters
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$10.8B
$5.29M 2.06%
65,284
-3,100
-5% -$266K
2016 Q4
5 quarters
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$31.3B
$4.38M 1.71%
36,800
– –
2017 Q3
2 quarters
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
$4.01M 1.57%
76,000
– –
2016 Q4
5 quarters
GTHX icon
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.81M 1.49%
103,000
+64,000
+164% +$1.71M
2017 Q3
2 quarters
BLUE icon
22
DELISTED
bluebird bio
BLUE
$3.41M 1.33%
1,544
– –
2017 Q3
2 quarters
KALV icon
23
DELISTED
KalVista Pharmaceuticals
KALV
$3.01M 1.17%
322,436
– –
2016 Q4
5 quarters
AGIO icon
24
Agios Pharmaceuticals
AGIO
$1.93B
$2.98M 1.16%
36,500
+16,500
+83% +$1.28M
2017 Q1
4 quarters
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$13.9B
$2.87M 1.12%
+19,000
New +$2.79M
2018 Q1
0 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2018 Portfolio in Review

As of Q1 2018, International Biotechnology Trust held 75 positions worth $256M, down 9.6% from $284M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust withdrew a net $13M in Q1 2018, closing 12 positions and reducing 12 holdings. Its most notable exit was Nektar Therapeutics, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Jazz Pharmaceuticals worth $2.87M.

  • International Biotechnology Trust's largest Q1 2018 buy was Jazz Pharmaceuticals: 19,000 shares worth $2.87M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2018, an estimated $9.88M increase.
  • International Biotechnology Trust's biggest Q1 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $8.06M.
  • International Biotechnology Trust fully exited Nektar Therapeutics in Q1 2018, selling an estimated $12.6M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $256M portfolio in Q1 2018.
  • International Biotechnology Trust opened 10 new positions and closed 12 in Q1 2018.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $256M.

Based on International Biotechnology Trust's 13F filing for Q1 2018, filed 15 May 2018.